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Objectives. We investigated the expression of atrial natriuretic
peptide (ANP) and brain natriuretic peptide (BNP) and their
genes in the hearts of patients with cardiac amyloidosis and those
with isolated atrial amyloidosis.
Background. The expression of ANP and BNP is augmented in
the ventricles of failing or hypertrophied hearts, or both. The
expression of ANP and BNP in the ventricles of hearts with
cardiac amyloidosis, which is hemodynamically similar to restric-
tive cardiomyopathy, is not yet known. ANP is the precursor
protein of isolated atrial amyloid.
Methods. We analyzed the immunohistocytochemical localiza-
tions of ANP and BNP as well as the expression of their mRNAs
by in situ hybridization in the myocardium and measured the
plasma levels of ANP and BNP in patients with cardiac amyloid-
osis.
Results. Four of the five right and all six left ventricular
endomyocardial biopsy specimens obtained from six patients with
cardiac amyloidosis were immunohistochemically positive for
both ANP and BNP; none of the biopsy specimens from eight
normal subjects were positive for ANP or BNP. All four of the
right atria obtained at operation showed positive immunoreac-
tions for both peptides. Electron microscopy identified specific
secretory granules in ventricular myoctyes of the patients with
cardiac amyloidosis, but not in ventricular myocytes from the
normal control subjects. Double immunocytochemical analysis
revealed the co-localization of ANP and BNP in the same granules
and that isolated atrial amyloid fibrils were immunoreactive for
ANP and BNP, whereas ventricular amyloid fibrils were negative
for both peptides. Both ANP mRNA and BNP mRNA were
expressed in the ventricles of the patients with cardiac amyloid-
osis but not in the normal ventricles. The autopsy study of four
patients with cardiac amyloidosis revealed an almost transmural
distribution of ANP and BNP, with predominance in the endocar-
dial side. Plasma BNP levels in the patients were markedly
elevated ([mean 6 SD] 1,165.1 6 561.2 pg/ml) compared with
those in the control subjects (8.9 6 6.0 pg/ml, p < 0.05).
Conclusions. Expression of ANP and BNP and their genes was
augmented in the ventricular myocytes of the patients with
cardiac amyloidosis. Both regional mechanical stress by amyloid
deposits and hemodynamic stress by diastolic dysfunction may be
responsible for the expression of the peptides in patients with
cardiac amyloidosis.
(J Am Coll Cardiol 1998;31:254–65)
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Atrial natriuretic peptide (ANP) is a cardiac hormone secreted
mainly from the atria and is involved in fluid, electrolyte and
vascular homeostasis (1,2). ANP is synthesized not only in the
atria but also in the ventricles of normal animals (3,4), and
ventricular ANP synthesis is increased in various pathologic
conditions, causing hemodynamic overload (5–9). Brain natri-
uretic peptide (BNP) has a striking similarity to ANP with
regard to both its amino acid sequence and pharmacologic
spectrum (10–12). Patients with congestive heart failure have
extremely high plasma levels of BNP, and the secretion of this
peptide from the ventricles is greatly augmented in these
patients (12,13). These studies suggest a pathophysiologic role
for ANP and BNP in cardiovascular disease as endogeneous
vasodilator and diuretic agents, and the finding that ANP or
BNP administration produces clinical improvement in patients
with congestive heart failure supports this hypothesis (14,15).
Dilated cardiomyopathy is one of the myocardial diseases
that cause heart failure, and thus augmented ANP and BNP in
ventricles afflicted with this disease have been well studied
(7–9,13). We found (16,17) that in the ventricles of hearts with
hypertrophic cardiomyopathy, the expression of ANP and BNP
was augmented despite the absence of heart failure. ANP or
BNP, or both, was found to be overexpressed in the myocytes
surrounding myocardial lesions, such as myocardial infarction
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and myocarditis (18–20). These findings suggest that focal as
well as hemodynamic stress is responsible for the ventricular
augmentation of these peptides. Cardiac amyloidosis presents
a hemodynamically restrictive pattern and is sometimes cate-
gorized as restrictive cardiomyopathy (21). In general, hearts
with cardiac amyloidosis preserve systolic function until the
terminal stage, but diastolic function is damaged, mainly as a
result of the mechanical disturbance of myocyte movement by
the diffuse deposition of amyloid. A previous study (22)
reported immunohistochemical ANP expression in the ventri-
cles of patients with restrictive cardiomyopathies, mainly idio-
pathic restrictive cardiomyopathy. However, ANP and BNP
have not yet been studied in detail in cardiac amyloidosis.
Another interesting relation between amyloidosis and na-
triuretic peptides is that in isolated atrial amyloidosis, amyloid
fibrils themselves show antigenicity against both ANP and
BNP, and thus ANP is regarded as the precursor protein of
isolated atrial amyloid (23–25). Amyloid in cardiac amyloidosis
is indeed derived from monoclonal immunoglobulin light chain
(26), but it is of interest as to whether it also contains the
immunogenicity of natriuretic peptides, in light of the above-
mentioned isolated atrial amyloidosis case.
In the present study, we investigated the expression and
tissue localization of ANP and BNP and their genes in the
myocardium of patients with cardiac amyloidosis by means of
immunohistochemical analysis at both the light and electron
microscopic levels and in situ hybridization histochemical
analysis. We also measured the plasma levels of both peptides
in these patients by means of radioimmunoassay.
Methods
Tissue specimens and experimental procedure. Myocar-
dial tissues (right atrial appendage or ventricle) were obtained
at biopsy, operation or autopsy from patients with cardiac
amyloidosis, patients with isolated atrial amyloidosis and con-
trol subjects. The tissue specimens were used for histologic,
electron microscopic and immunohistochemical studies at both
the light and electron microscopic levels and for in situ
hybridization histochemical analysis to detect ANP and BNP
and their genes. Blood sampling was also performed in some
patients to measure the plasma concentrations of ANP and
BNP (by radioimmunoassay) and other humoral factors.
Endomyocardial biopsy. Six patients who met the clinical
and histologic criteria for the diagnosis of restrictive cardio-
myopathy on the basis of cardiac involvement of AL amyloid-
osis (systemic amyloidosis with light chain deposition) were
enrolled in the study (five men, one woman; 46 to 71 years old,
mean [6SD] 57 6 8). Clinical findings included the presence
of monoclonal protein in serum or urine, the involvement of
other organs with amyloidosis, the absence of underlying
diseases other than myeloma and clinical syndromes, such as
nephrotic and carpal tunnel syndrome. The classification of
restrictive heart disease was based on the presence of classical
restrictive hemodynamic features at catheterization or by
Doppler echocardiographic examination. The histologic diag-
nosis was confirmed at biopsy by the presence of amyloid
deposits identified by a positive staining reaction with alkaline
Congo red with dichronic birefringence that was not attenu-
ated after treatment with KMnO4 (27). No patient had coro-
nary artery disease, myocardial infarction, valvular heart dis-
ease or any heart disease other than cardiac amyloidosis.
Control endomyocardial biopsy specimens were taken from
eight patients with clinically suspected cardiac disease because
of chest pain, syncope, slight electrocardiographic changes or
arrhythmia. Noninvasive and invasive examinations, including
biopsy, revealed no organic heart disease in these patients.
Two-dimensional echocardiographic examination was per-
formed in all 14 patients. The left ventricular mass index was
calculated by the method of Feneley et al. (28). All patients
underwent biventricular cardiac catheterization, biplane left
ventriculography and selective coronary angiography by stan-
dard techniques. During the procedure, endomyocardial bi-
opsy samples were taken from both the right and left ventricles
in five of the six patients with cardiac amyloidosis and all eight
control patients and from only the right ventricle in one patient
with cardiac amyloidosis. Two to five pieces of tissue were
obtained from each site. The largest specimens were immedi-
ately immersed in 10% buffered formalin solution, and other
pieces were fixed with 2.5% glutaraldehyde solution. Some
specimens from two patients with cardiac amyloidosis and
three control patients were fixed with 4% cold paraformalde-
hyde solution for 4 h at 4°C. After being soaked in graded
sucrose, the specimens were embedded in cryomold by dry
ice-acetone. Table 1 summarizes the clinical data of the
patients and histologic findings in the endomyocardial biopsy
specimens.
Right atrial appendages resected at operation. Right atrial
appendages were obtained from four patients who underwent
aortocoronary bypass surgery. These specimens were treated in
the same way as the endomyocardial biopsy specimens.
Autopsy hearts. Four autopsy hearts from patients with
cardiac amyloidosis (other than the previously described pa-
tients) were studied. All four patients had died of heart failure
accompanied by prominent congestion of the lungs, liver and
kidneys. The hearts showed extensive deposits of amyloid and
fibrosis. Four hearts from age- and gender-matched subjects
with neither amyloidosis nor other cardiac disease served as
control hearts. The control patients died of noncardiac causes
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
ELISA 5 enzyme-linked immunosorbent assay
ET-1 5 endothelin-1
LVEDP 5 left ventricular end-diastolic pressure
LVMI 5 left ventricular mass index
PBS 5 phosphate-buffered saline
PRA 5 plasma renin activity
SSC 5 standard saline citrate
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Table 1. Data of Patients Who Underwent Biopsy or Operation
Specimen
and Pt
Group
Age (yr)/
Gender
HR
(bpm)
CI
(liters/min
per m2)
EDVI,
ESVI
(ml/m2)
LVEF
(%)
LVSP,
LVEDP
(mm Hg)
RVSP,
RVEDP
(mm Hg)
IVST,
LVPWT
(mm)
LVMI
(ml/m2)
Size of
Myocyte:
RVB, LVB
(mm)
Serum
Creatinine,
BUN
(mg/dl)
Plasma ANP,
BNP
(pg/ml)*
PRA
(ng/ml per h),
Aldosterone
(pg/ml)*
Plasma
ET-1
(pg/ml)*
Ventricle
Amyloidosis
Pt A1 52/M 80 3.90 73, 67 85, 40, 12, 180 20.0, 1.0, —, —, —
24 15 10 13 26.0 16.0 — —
Pt A2 46/M 88 3.30 53, 31 128, 24, 12, 182 17.9, 1.1, —, —, —
36 26 5 14 21.9 12.0 — —
Pt A3 59/M 80 2.06 60, 53 120, 40, 14, 191 17.2, 1.0, 47.0, 0.4, 5.39
28 20 15 13 17.0 18.0 640.5 10.0
Pt A4 58/M 105 3.94 76, 76 106, 34, 12, 172 14.4, 0.6, —, —, —
18 10 7 12 17.9 10.0 — —
Pt A5 53/M 76 3.42 98, 47 129, 43, 12, 182 22.4, 1.3, 211.5, 0.4, 4.72
52 24 7 11 22.2 11.0 1,097.8 26.0
Pt A6 71/F 130 2.47 46, 61 124, 34, 15, 224 —, 0.7, 911.6, 2.8, 1.47
18 17 10 14 16.3 13.0 1,756.9 160.0
Mean 6 SD 57 6 8 93 6 21 3.18 6 0.77 68 6 19, 56 6 16 113 6 15,† 36 6 7, 13 6 1,‡ 188 6 18‡ 18.4 6 3.0,‡ 1.0 6 0.3, 390.0 6 459.1, 1.2 6 1.4, 3.86 6 2.10†
(5/1) 32 6 18 19 6 6‡ 9 6 4 13 6 2‡ 20.2 6 3.9† 13 6 3 1,165.1 6 561.2† 65 6 82
Control (n 5 8)
Mean 6 SD 57 6 13 80 6 20 3.03 6 1.16 69 6 10, 75 6 8 141 6 14, 32 6 5, 11 6 1, 113 6 23 13.4 6 1.3, 1.1 6 0.3, 13.4 6 9.0, 1.2 6 1.2, 1.57 6 0.74
(6/2) 17 6 5 9 6 3 6 6 2 11 6 1 15.8 6 1.2 17 6 5 8.9 6 6.0 61 6 19
RAA
ACBG (n 5 4)
Mean 6 SD 62 6 15 73 6 24 3.17 6 1.12 85 6 33, 66 6 31 147 6 26, 33 6 8, 10 6 1, 115 6 13 —, 1.0 6 0.1, —, —, —
(3/1) 37 6 43 9 6 3 8 6 4 10 6 0 — 15 6 3 — —
*Plasma levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), plasma renin activity (PRA), aldosterone and endothelin (ET)-1 were measured in three patients with cardiac amyloidosis and six control
subjects. †p , 0.05, ‡p , 0.01, significant difference versus other groups. ACBG 5 aortocoronary bypass graft; bpm 5 beats/minute; BUN 5 blood urea nitrogen; CI 5 cardiac index; EDVI and ESVI 5 left ventricular
end-diastolic and end-systolic volume index, respectively; F 5 female; HR 5 heart rate; IVST and LVPWT 5 interventricular septal and left ventricular posterior wall thickness by two-dimensional echocardiography,
respectively; LVB 5 left ventricular biopsy; LVEF 5 left ventricular ejection fraction; LVMI 5 echocardiographic left ventricular mass index; LVSP and LVEDP 5 left ventricular systolic and end-diastolic pressure,
respectively; M 5 male; Pt 5 patient; RAA 5 right atrial appendage; RVB 5 right ventricular biopsy; RVSP and RVEDP 5 right ventricular systolic and end-diastolic pressure, respectively.
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(cancer in two patients, a traffic accident in one and cerebro-
vascular disease in one). No autopsy heart had any congenital
anomalies, significant stenosis of the major coronary arteries
or valvular disease. All subjects were autopsied within 12 h of
death. The autopsy data are summarized in Table 2.
After fixation with 10% buffered formalin, the right atrial
free wall and appendage were resected. The ventricles were cut
into serial transverse slices from the base to the apex, and a
slice from the midpoint of the heart was cut into six to eight
blocks. The slices were embedded in paraffin and sectioned at
a thickness of 4 mm.
Histologic evaluation. Light microscopic observations of
the sections were made after hematoxylin-eosin staining and
measurement of myocyte size (mean diameter 30 to 50 myocytes/
specimen). The paraffin sections were also stained with alka-
line Congo red or with Daylon and examined under polarized
light.
Transmission electron microscopy. Biopsied specimens of
the ventricles from three patients with amyloidosis and from
three control subjects and three atrial tissues obtained at
operation were fixed in 2.5% glutaraldehyde at 4°C, followed
by postfixation with 1% osmium tetroxide. The specimens were
then dehydrated and embedded in Epon. Ultrathin sections
were stained with uranyl acetate and lead citrate and viewed
under an electron microscope (model H-600, Hitachi, Tokyo,
Japan).
Immunohistochemical analysis. Monoclonal antibodies
against human BNP-32 and alpha-human ANP were prepared
as previously described (12,29).
Serial 4-mm paraffin sections were alternately immuno-
stained with the antibodies to ANP and BNP to compare their
distribution. Immunostaining was done according to the indi-
rect immunoperoxidase method reported previously, with
some modifications (9,13,16–20). In the biopsy and surgical
samples, the largest two specimens from each side of the heart
were used, and sections from three different depths in the
blocks were subjected to immunostaining. In the autopsy cases,
whole ventricular transverse sections were used. Antigen re-
trieval was performed by soaking the deparaffinized sections in
hot water (95°C) for 10 min. Intrinsic peroxidase activity was
blocked by incubation with 0.3% hydrogen peroxide for
20 min, and nonspecific binding was blocked with normal goat
serum. As the primary antibody, the monoclonal antibody was
added at the dilution of 1:1,000 to the sections, followed by
incubation for 48 h at 4°C. Next, peroxidase-conjugated
F(ab9)2 fragment of the secondary antibody (goat anti-mouse
IgG[H1L], Jackson Immunoresearch Laboratories) was
added for 45 min at room temperature. The sections were
subsequently stained with 45 mg of 3,39-diaminobenzidine
tetrahydrochloride (Sigma) and 0.05% hydrogen peroxide in
100 ml of 0.05 mol/liter Tris buffer for 3 min at room
temperature. Between each step, the sections were washed
four times (for 10 min each) with 0.01 mol/liter phosphate-
buffered saline (PBS). Finally, counterstaining with hematox-
ylin was carried out.
The specificity of the immunohistochemical reaction was
tested by preabsorption of the primary antibody with the
corresponding peptide antigen (1 nmol peptide/ml of diluted
antigen) and substitution of the primary antibody with nonim-
mune mouse serum. In addition, to exclude the possibility of
cross-reaction between ANP and BNP, the primary antibody
was preabsorbed with heterogeneous antigen (1 nmol/ml).
Immunocytochemical analysis at electron microscopic
level. Small pieces of the biopsy specimens from two patients
with cardiac amyloidosis and from three control subjects and
two surgical specimens of right atrial appendages were fixed in
2.5% phosphate-buffered glutaraldehyde without postfixation
by osmium tetroxide. The specimens were washed, dehydrated
and embedded in Epon medium. Ultrathin sections of 80 nm
were cut and mounted on bare 300-mesh nickel grids. For
Table 2. Autopsy Data
Group
Age (yr)/
Gender
Heart Wt
(g)
IVS
Thickness
(mm)
LVFW
Thickness
(mm)
Staining Pattern
ANP BNP
End Mid Epi End Mid Epi
Amyloidosis (n 5 4)
Pt B1 64/F 490 20 20 1, d 1, d 1, f 1, f — —
Pt B2 73/F 460 15 15 1, d — — 1, f — —
Pt B3 78/M 410 14 12 1, d 1, d 1, f 1, d 1, d 1, f
Pt B4 72/M 605 20 18 1, d 1, d 1, f 1, d 1, d 1, f
Mean 72 491 17 16
6SD 66 683* 63† 64
(2/2)
Control (n 5 4) All All All All All All
Mean 72 286 12 12 — — — — — —
6SD 65 623 61 61
(2/2)
*p , 0.01, †p , 0.05, significant difference versus control group. d 5 diffuse; End, Mid and Epi 5 subendocardial,
middle and subepicardial one-third layer of transversely sectioned ventricular walls, respectively; f 5 focal; IVS 5
interventricular septum; LVFW 5 left ventricular free wall; Wt 5 weight; 1 5 positive; other abbreviations as in Table 1.
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double staining for ANP and BNP, sequential immunogold
staining of the two faces of each ultrathin section was per-
formed as previously described, with slight modifications
(13,30). In the first staining sequence, only one side of the
section was exposed to the solutions. The grids were floated,
tissue sections face down, on drops of PBS containing 3%
normal goat serum for 30 min before incubation with anti-BNP
antibody (diluted 1:500) for 20 h at 4°C. After being washed in
PBS, the sections were placed on drops of 10-nm gold-labeled
goat anti-mouse IgG (diluted 1:20, Amersham, UK) for 1 h
and then washed in PBS, rinsed in distilled water and dried.
The grids were then turned over, and the other side of the
sections was labeled according to the same procedure using
anti-ANP antibody (diluted 1:250) for 20 h at 4°C and 5-nm
gold-labeled anti-mouse IgG (diluted 1:20, Amersham) for 1 h
at room temperature. After completion of the incubation
procedures, the grids were rinsed in PBS and distilled water
and counterstained with uranyl acetate and lead citrate before
electron microscopic examination.
RNA probes and in situ hybridization histochemistry. The
581-base pair SacI–PstI fragment of human ANP cDNA (31)
was subcloned into pBluescript SK2 (Stratagene). This vector
was linearized with SacI or PstI. The SacI overhanging ends of
the linearized DNA templates were modified to blunt ends
with a Blunt-end kit (Takara Shuzo, Otsu, Japan). Digoxigenin-
labeled riboprobes were transcribed using a DIG RNA label-
ing kit (Boehringer Mannheim Biochemica, Mannheim, Ger-
many). Antisense ANP and sense ANP riboprobes were
transcribed with T7 or T3 RNA polymerase, respectively.
The cDNA of human BNP prepared by reverse transcrip-
tase-polymerase chain reaction (32) was subcloned into the
vector pCRII using a T-A cloning kit (Invitrogen). The se-
quence of BNP cDNA subcloned into the plasmid was deter-
mined by the dideoxy chain termination method. This vector
was linearized with EcoR or HindIII. Antisense and sense BNP
riboprobes were transcribed with SP6 and T7 RNA polymer-
ase, respectively.
The specificity of the riboprobes was also confirmed by
Northern blotting using a DIG nucleic acid detection kit
(Boehringer).
Six-micrometer thick cryosections were mounted on glass
slides coated with silane. The hydrated sections were rinsed in
PBS and then placed subsequentially in 2 mg/ml of proteinase
K in PBS for 20 min at 37°C and postfixed in 4% paraformal-
dehyde for 10 min. They were then placed in 0.2 N HCl for
10 min. The slides were rinsed in PBS between each of these
procedures, which were carried out at room temperature,
unless otherwise stated. They were hybridized overnight at
50°C in hybridization buffer (Hybrisol I containing 50% form-
amide [Oncor]) at a probe concentration of 200 ng/ml. The
slides were then washed in 2 3 standard saline citrate (SSC)
with 50% formamide at 50°C for 15 min twice and incubated
with RNase A (Boehringer) for 30 min at 37°C. Finally, the
slides were washed in 2 3 SSC and in 0.2 3 SSC for 15 min
each at 50°C. For immunodetection, the DIG nucleic acid
detection kit (Boehringer) was used.
To ensure the specificity of the mRNA signals, in situ
hybridization with sense probes and RNase digestion of the
sections before hybridization were performed as the negative
controls.
Plasma sampling. Of the subjects who underwent the
endomyocardial biopsy, plasma samples were obtained from
three patients with cardiac amyloidosis and six control subjects
within 1 week before the biopsy procedure. Blood was with-
drawn from the antecubital vein while the subject was in a
recumbent position in the morning, after medications had been
discontinued the night before. The samples were immediately
transferred to chilled glass tubes containing Na2EDTA
(1 mg/ml) and aprotinin (1 million IU/ml) and centrifuged at
4°C. Plasma was frozen immediately and stored at 270°C until
assay.
Measurement of plasma ANP and BNP. Measurement of
plasma levels of ANP and BNP was performed by radioimmu-
noassay, as previously reported (8,12).
Measurement of plasma renin activity, aldosterone and
endothelin-1. Plasma renin activity (PRA) and plasma aldo-
sterone concentrations were measured with commercially
available kits, renin radioimmunoassay beads (Dainabot, To-
kyo, Japan) and an aldosterone radioimmunoassay kit II
(Dainabot), respectively.
The plasma endothelin-1 (ET-1) concentration was mea-
sured with an enzyme-linked immunosorbent assay (ELISA)
kit (Wako Pure Chemicals, Osaka, Japan) according to the
manufacturer’s instructions. This ELISA is a two-step sand-
wich method using a monoclonal antibody that recognizes the
N-terminal of ET-1 and a peroxidase-conjugated polyclonal
antibody that recognizes the C-terminal of ET-1. In this
system, cross-reactivity with ET-3, or big ET-1, is , 0.4%.
Statistical analysis. The clinicopathologic values are ex-
pressed as the mean value 6 SD. Statistical analyses were
performed using the Fisher exact test, Student t test or one-way
analysis of variance, followed by the Newman-Keul multiple
comparison test when appropriate. A p value , 0.05 was
considered significant.
Results
Hemodynamic and histopathologic characterization of pa-
tients. Table 1 summarizes the hemodynamic and angio-
graphic data of the patients who underwent biopsy or opera-
tion. Left ventricular end-diastolic pressure (LVEDP) was
significantly elevated in patients with cardiac amyloidosis com-
pared with control group values. Right ventricular pressure
records showed a dip and plateau pattern in all patients with
cardiac amyloidosis but not in the control subjects. However,
left ventricular ejection fraction and volume indexes were not
different between the two groups. Hemodynamic variables
showed no significant differences between patients who under-
went aortocoronary bypass surgery and control subjects.
In both the right and left ventricular biopsy specimens, the
myocyte size was larger in the cardiac amyloidosis group (right:
18.4 6 3.0 mm, left: 20.2 6 3.8 mm) than in the control group
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(right: 13.4 6 1.3 mm, left: 15.8 6 1.2 mm). Specimens from the
cardiac amyloidosis group showed amyloid deposition in the
vascular structures and interstitium among myocytes or be-
neath the endocardium. A small amount of amyloid deposit
was noted in two of the four right atrial tissue specimens
obtained at operation (isolated atrial amyloid).
Immunohistochemical expressions of ANP and BNP. Con-
trol sections incubated with nonimmune mouse serum as the
primary antibody, or with the primary antibody preabsorbed
with homologous antigen, showed no specific immunoreaction.
Moreover, staining with the antibody to human BNP-32 was
not reduced by preabsorption with alpha-human ANP, or vice
versa.
In the right atrial appendages, almost all atrial myocytes
showed immunoreactivity for ANP, whereas BNP was predom-
inantly localized in the myocytes of the subendocardial side
and was rare on the epicardial side (Fig. 1). Although these
peptides were generally not found in the endocardium, epicar-
dium or connective tissue, their immunoreactions were noted
on small deposits of atrial amyloid (Fig. 1).
None of the biopsied ventricles, neither the right nor left
side, of the control group showed immunoreactivity for ANP
or BNP. In contrast, four of five right and all six left ventricular
biopsy specimens from the cardiac amyloidosis group showed
immunoreactivity for both ANP and BNP (Fig. 2). In speci-
mens from both sides, the incidence was significantly higher in
the cardiac amyloidosis group than in the control group. The
endocardium, connective tissue and vasculature were not
Figure 1. Light micrographs showing transmu-
ral gradient of immunohistochemical expres-
sion of ANP (A) and BNP (B) in a right atrial
appendage. Note that ANP is distributed in
atrial myocytes transmurally, but BNP is pre-
dominantly localized in the endocardial side
(asterisks). The right atrial appendage with
isolated atrial amyloidosis stained with Congo
red (C) and immunohistochemically with anti-
ANP (D) and anti-BNP antibody (E) is shown.
Small amyloid deposits and ANP immunoreac-
tions are seen in the subendocardial connective
tissue. A and B: 340; C to E: 3200, reduced by
35%.
Figure 2. Light micrographs of left ventricular
endomyocardial biopsy specimen from a patient
with cardiac amyloidosis A, Hematoxylin-eosin
stain. B, Congo red stain with dichronic bire-
fringence. C and D, Immunohistochemical ex-
pression of ANP (C) and BNP (D). Vascular
and interstitial amyloid deposits are seen. ANP
and BNP immunoreactions are present in the
myocytes but not in the amyloid deposits. 3200,
reduced by 35%.
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immunoreactive to ANP or BNP. Unlike the atrial amyloid,
the ventricular AL amyloid in cardiac amyloidosis did not show
ANP or BNP immunoreactivity (Fig. 2).
ANP or BNP immunoreactive products were not seen in the
ventricles of any autopsy control heart. However, ANP and
BNP immunoreactions were seen in the all ventricles with
cardiac amyloidosis (Table 2). The immunoreactions were
exclusively noted in myocytes but not in the endocardium,
epicardium or interstitium, including amyloid fibers. The ANP-
positive myocytes were distributed transmurally in three of the
four cases, and BNP-positive myocytes were distributed trans-
murally in two of the four cases; not only in the subendocar-
dium but also in the subepicardium (Fig. 3). Both the density
of the positive myocytes and the intensity of staining were
more predominant on the endocardial side. The myocytes
surrounding amyloid deposits tended to show more intense
staining. Our observations of the serial sections showed that
the distribution of ANP- and BNP-positive myocytes was
similar.
Electron microscopy. In the atrial myocytes, many secre-
tory granules were gathered around the nuclei but were also
found frequently in the peripheral cytoplasm (Fig. 4). A
deposit of amyloid fibrils was found in one atrial specimen used
for electron microscopy. Secretory granules were not noted in
any ventricular myocytes of the biopsy specimens obtained
from the normal control subjects. In contrast, myocytes con-
taining secretory granules similar to the atrial myocytes were
found in all biopsy specimens from patients with cardiac
amyloidosis (Fig. 4). All cardiac amyloidosis specimens con-
tained amyloid fibrils to some degree in the interstitium.
Immunocytochemistry at the electron microscopic level.
The control studies using nonimmune mouse serum as the
primary antibody and preabsorption tests for double immuno-
cytochemical analysis at the electron microscopic level showed
Figure 3. Light micrographs of left ventricle
from an autopsied heart of a patient with
cardiac amyloidosis showing immunohisto-
chemical expression of ANP (A1 and A2) and
BNP (B1 and B2) in the endocardial (End [A1
and B1]) and epicardial side (Epi [A2 and B2]).
In this patient, ANP and BNP expression is
transmural. 3100, reduced by 35%.
Figure 4. Electron micrographs of left ventricular endomyocardial
biopsy specimen from a patient with cardiac amyloidosis showing
specific granules in myocytes. A, Electron-dense specific granules
(arrows) are seen in the perinuclear region. N 5 nucleus; Lp 5 lipofuscin.
37,000, reduced by 35%. B, Higher magnification of panel A. Golgi
complex (GC) is seen near the specific granules. Mt 5 mitochondria;
Mf 5 myofibrils. 320,000, reduced by 35%. C, Perimyocyte amyloid
fibrils (Af) and a myocyte containing specific granules (arrows). The
plasma membrane of the myocyte is indicated by arrowheads. 36,000,
reduced by 35%. Bars 5 1 mm (A and C) and 0.5 mm (B).
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no cross-reactions between the first and second staining se-
quences.
Gold particles were concentrated on the myocyte secretory
granules. In the atrial myocytes, two types of secretory granules
presenting different immunostaining patterns were noted as
previously reported (13,30): monohormonal granules labeled
only with small gold particles, indicating ANP (type 1 gran-
ules); and multihormonal granules containing both small and
large gold particles, respectively, indicating ANP and BNP
(type 2 granules) (Fig. 5). The amyloid fibrils in an atrial
specimen were positive for both ANP and BNP (Fig. 5). Gold
particles did not gather on any organelles other than myocyte
granules and amyloid fibrils in the right atrial appendages.
In the ventricular myocytes of the normal control subjects,
we found neither secretory granules nor accumulations of gold
particles. However, in the ventricular myocytes of the cardiac
amyloidosis specimens, the gold particles then were concen-
trated on secretory granules were type 2, showing an intense
immunoreaction for both ANP and BNP. Unlike the isolated
atrial amyloid, the ventricular amyloid fibrils of the cardiac
amyloidosis were not positive for ANP or BNP immunoreac-
tion (Fig. 5).
In situ hybridization. The signals of digoxigenin-labeled
riboprobes hybridized with mRNA of ANP and BNP were seen
as dark precipitates in the cytoplasm of atrial myocytes (Fig. 6).
Hybridization signals were observed exclusively in the myo-
cytes and were not seen in any connective tissue or vasculature.
The signals for ANP were stronger than those for BNP in all
atrial specimens. Neither the sense ANP or sense BNP ribo-
probe yielded any hybridization (Fig. 6).
No hybridization signal was noted in any ventricular biopsy
specimen from the control subjects. However, the signals for
both ANP mRNA and BNP mRNA were noted in the ventric-
ular biopsy specimens from two patients with cardiac amyloid-
osis: in both the right and left ventricular specimens from one
patient and in the left ventricular specimen from the other
(Fig. 6). The signal intensities of ANP mRNA and BNP
mRNA showed no marked difference, in contrast to those in
Figure 5. Double immunocytochemical studies for
ANP and BNP in a right atrial tissue specimen
obtained at operation (A and B) and ventricular
tissue from a patient with cardiac amyloidosis (C and
D). Smaller gold particles (5 nm) indicate ANP, and
bigger particles (10 nm) indicate BNP. A, Arrows
indicate granules containing ANP alone (type 1
granules); granules without arrows contain both
ANP and BNP (type 2 granules). 330,000, reduced
by 35%. B, Amyloid fibrils of isolated atrial amyloid-
osis on which both smaller and larger gold particles
are concentrated. 37,000, reduced by 35%. C, Ven-
tricular granules show immunoreactions for both
ANP and BNP (type 2 granules). The labeling inten-
sities of BNP are more prominent in ventricular
granules than within atrial granules. 330,000, re-
duced by 35%. D, Amyloid fibrils, in a ventricle from
a patient with cardiac amyloidosis, are labeled with
neither the smaller nor the larger gold particles.
37,000, reduced by 35%. Bars 5 0.5 mm.
Figure 6. In situ hybridization immunohistochemical studies for ANP
mRNA and BNP mRNA in a right atrial tissue specimen obtained at
operation (A to D) and a left ventricular endomyocardial biopsy tissue
specimen from a patient with cardiac amyloidosis (E and F). 3200,
reduced by 35%. A and B, Serial sections treated with, respectively,
antisense and sense probes for ANP mRNA. C and D, Serial sections
treated with antisense and sense probes for BNP mRNA, respectively.
E and F, Serial sections treated with the antisense probe for ANP
mRNA and BNP mRNA, respectively.
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the atria. Neither sense ANP or sense BNP riboprobe yielded
any hybridization.
Plasma levels of ANP, BNP and other humoral factors.
The plasma levels of both ANP and BNP were significantly
higher in patients with cardiac amyloidosis than in control
subjects, but the elevation of plasma BNP level was more
marked (Table 1). In one patient with cardiac amyloidosis in
particular, the plasma BNP level was markedly elevated
(640.5 pg/ml) despite a slight elevation of the plasma ANP
level (47.0 pg/ml). The mean ratio of BNP to ANP in the
plasma was 6.9 6 6.0 in the cardiac amyloidosis group and
0.8 6 0.4 in the control group.
Patients with cardiac amyloidosis showed levels of PRA and
aldosterone similar to those in the control subjects, whereas
patients had a more than twofold higher level of ET-1 than did
the control subjects (3.86 6 2.10 vs. 1.57 6 0.74 pg/ml); the
difference was significant (p , 0.05) despite the small number
of samples (Table 1).
To explore the relation between the humoral factors and
cardiac hypertrophy, we examined the correlations between
ANP, BNP, ET-1 and left ventricular mass index (LVMI).
Both BNP and ANP levels showed a significant linear corre-
lation with LVMI: r 5 0.886, p , 0.001 for BNP; r 5 0.730, p ,
0.05 for ANP. When the plots were fit exponentially, the
correlation coefficients were higher: r 5 0.891, p , 0.001 for
BNP; r 5 0.842, p , 0.005 for ANP (Fig. 7). ET-1 was not
significantly correlated with LVMI (r 5 0.540, p 5 NS for
linear fit; r 5 0.512, p 5 NS for exponential fit) (Fig. 7).
We also checked the correlations between ANP, BNP and
LVEDP to further explore the relation between the natriuretic
peptides and diastolic dysfunction. Both BNP and ANP levels
showed a significant correlation with LVEDP when the plots
were exponentially fit, with the higher correlation coefficient
between BNP and LVEDP: r 5 0.880, p , 0.001 for BNP; r 5
0.756, p , 0.05 for ANP (Fig. 8).
Discussion
Overexpression of natriuretic peptides in ventricles with
cardiac amyloidosis. The present study revealed the diffuse
expression of natriuretic peptides in the autopsied ventricles of
patients with end-stage cardiac amyloidosis who died of heart
failure. In these specimens, the expression was almost trans-
mural but was more prominent in the endocardial than in the
epicardial side. Ventricular wall stress is greater on the endo-
cardial side than on the epicardial side (33,34). Thus, the result
suggests that the “hemodynamic overload” hypothesis for the
ventricular expression of these peptides (8,9,12,13) remains
true in patients with cardiac amyloidosis. However, the present
study also showed a high incidence of augmented ANP and
BNP expression in the ventricular endomyocardial biopsy
specimens of patients with cardiac amyloidosis who had rela-
tively well preserved systolic function but poor diastolic func-
tion. These findings suggest that hemodynamic stress, particu-
larly during the diastolic phase due to diastolic dysfunction, is
important for the overexpression of ventricular natriuretic
peptides in cardiac amyloidosis. In addition, the myocytes
neighboring amyloid deposits tended to show more intense
staining. Amyloid deposits may produce regional mechanical
stress by restricting myocyte motion and interfering with their
cooperative movement. Previous studies (9,13,16 –18,20)
pointed out a close association of ventricular expression of
these peptides with a histologic abnormality, such as fibrosis in
hearts with dilated and hypertrophic cardiomyopathy, myocar-
dial infarction and myocarditis. Thus, regional stress related to
amyloid deposits may be another contributor to overexpression
of the peptides in cardiac amyloidosis. The transmural pattern
of the natriuretic peptides in cardiac amyloidosis is considered
to agree with diffuse and transmural distribution of amyloid
deposits in the interstitium. Therefore, both hemodynamic
stress accompanied by ventricular diastolic dysfunction and
regional mechanical stress restricting myocardial movement by
amyloid deposits may be important triggers for the expression
of these peptides in patients with cardiac amyloidosis.
Figure 7. Plots of correlations between the plasma
concentrations of ANP, BNP and ET-1 and LVMI.
Solid circles 5 patients with cardiac amyloidosis;
open circles 5 normal control subjects.
Figure 8. Plots of correlations between the plasma concentrations of
ANP and BNP and LVEDP. Symbols as in Figure 7.
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Subcellular distribution of natriuretic peptides in cardiac
amyloidosis and isolated atrial amyloidosis. We identified
ultrastructural specific secretory granules in the ventricular
myocytes of patients with cardiac amyloidosis. This finding is
compatible with previous reports on the occurrence of specific
granules in the stressed ventricular myocytes of cardiomyo-
pathic hamsters (35), spontaneously hypertensive rats (36) and
patients with dilated cardiomyopathy (13). In the present
study, electron microscopic immunocytochemical analysis re-
vealed that similar to dilated cardiomyopathy (13), all granules
detected in the ventricular myocytes of cardiac amyloidosis
showed an immunoreaction for both ANP and BNP, in con-
trast to atrial myocytes, where two types of granules were
found: one with ANP immunoreactivity only; the other with
both ANP and BNP immunoreactivity. The different distribu-
tion of the granule types between the ventricular and atrial
myocytes may reflect a more active production of BNP in the
ventricles. It has been reported (3,12,32) that both natriuretic
peptides are secreted from ventricles through a constitutive
pathway. Immunoreactivity for these peptides may thus also
exist in the cytoplasm or in organelles other than granules.
However, they are not likely to be in a concentrated form
outside the granules and therefore would not be identified by
electron microscopic immunocytochemical analysis. The pres-
ence of granules immunoreactive for both natriuretic peptides
in the ventricular myocytes of patients with cardiac amyloidosis
suggests that these peptides are, at least in part, synthesized
simultaneously and secreted together by the same granules.
In the isolated atrial amyloid, we detected immunogenicity
of ANP and BNP at the light or electron microscopic level, or
both. We observed these immunogenicities in the atria of
nonfailing hearts, whereas Pucci et al. (24) observed them in
the atria of failing hearts. This finding supports the hypothesis
that ANP and BNP or their precursor peptides are constituents
of amyloid fibrils of isolated atrial amyloidosis (23,24). In
contrast, neither ANP nor BNP immunogenicity was detected
in the ventricular amyloid fibrils of the cardiac amyloidosis
specimens by light and electron microscopic immunohistocy-
tochemical analysis in the present work. This is not a surprising
result considering that amyloid fibrils of AL amyloidosis are
induced from the light chains of monoclonal immunoglobulins
(26), but our finding confirmed that ANP and BNP are not
additional components of the amyloid fibrils in cardiac amy-
loidosis despite the fact that the ventricular myocytes of
patients with cardiac amyloidosis contain both peptides. This
phenomenon may reflect a more active and rapid turnover of
these peptides in the ventricle than in the atrium.
Relation between plasma BNP levels and diastolic dysfunc-
tion. Plasma BNP levels in patients with cardiac amyloidosis
were surprisingly high such that they showed significant differ-
ence from those values in the control subjects (n 5 6) despite
the small sample number (n 5 3). Renal function was not
impaired in our patients with cardiac amyloidosis (Table 1).
Therefore, the increase in circulating ANP and BNP in these
patients does not seem to be due to decreased clearance. Mean
left ventricular ejection fraction (systolic function) was not
greatly decreased in these three patients (54 6 7%), but
LVEDP (diastolic function) was greatly increased (20 6
4 mm Hg), reminiscent of the high plasma BNP levels in
patients with hypertrophic cardiomyopathy (17,37,38). Accord-
ing to our previous studies (17,38), plasma BNP levels in
hypertrophic cardiomyopathy were higher in patients with than
in those without a left ventricular outflow tract obstruction.
Ventricular BNP expression also positively correlated with
histologic changes and an LVEDP pressure elevation (17).
Because BNP is secreted mainly from the ventricles (32),
ventricular BNP may contribute much to plasma BNP levels in
disease states. Cardiac amyloidosis resembles hypertrophic
cardiomyopathy in presenting diastolic dysfunction. Thus, both
in hypertrophic cardiomyopathy (the obstructive type in par-
ticular) and cardiac amyloidosis, the extreme increase in
plasma BNP may be due to a ventricular overexpression of
BNP that is triggered by the combined effects of hemodynamic
stress, mainly at diastole, and regional mechanical stress
induced by histologic abnormalities. We therefore postulate
that the expression of BNP is highly sensitive to ventricular
diastolic dysfunction and regional mechanical stress and that
BNP expression is one of the specific compensatory mecha-
nisms in such disease states. BNP has been reported (39) to be
released in increased amounts throughout the ventricular
myocardium but principally from the infarct zone in patients
with an old myocardial infarction, presumably in response to
increased regional wall stress. In addition, a recent study (40)
showed beneficial hemodynamic and neurohormonal effects of
a BNP infusion during exercise in patients with isolated
diastolic heart failure. These findings support our speculation.
The question arises as to whether the activation of ANP and
BNP as observed is unique to cardiac amyloidosis among
restrictive cardiomyopathies. We observed the overexpressions
of ANP and BNP in the endomyocardial biopsy specimens
from a patient with idiopathic restrictive cardiomyopathy and
from a patient with endocardial fibroelastosis (unpublished
data). Moreover, the present study revealed good correlations
between the plasma levels of the peptides and LVEDP (Fig. 8).
Taking these findings together with the report of Edwards et al.
(22), the overexpression of the ventricular natriuretic peptides
as observed may be extended to restrictive cardiomyopathies
with an etiology other than cardiac amyloidosis.
Relation between natriuretic peptides and other variables.
The present patients with cardiac amyloidosis showed levels of
PRA and aldosterone similar to those in the control subjects.
However, ET-1 levels were more than twofold higher in the
patients than in the control subjects. Physiologic effects of
ET-1 (e.g., an increase in systemic vascular resistance or a
decrease in cardiac output [41]), were not observed in our
patients with cardiac amyloidosis; rather, this group was rela-
tively hypotensive (Table 1). It is therefore conceivable that
ANP and BNP may counteract the hemodynamic effects of
ET-1 in the patients with cardiac amyloidosis.
In the present study, both BNP and ANP showed a signif-
icantly positive correlation with LVMI. BNP was more closely
correlated with LVMI than was ANP. ET-1 also had a
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tendency toward a positive correlation with LVMI that was not
significant. Thus, BNP may be the best marker among these
humoral factors for cardiac hypertrophy. However, it is not
clear at present whether these differences in the findings
among ANP, BNP and ET-1 are significant or are attributable
to the low number of data analyzed. More extensive studies are
necessary for elucidation.
Conclusions. The major findings of the present study are as
follows: 1) The expression of ANP and BNP was augmented at
both the peptide and mRNA levels in ventricular myocytes of
cardiac amyloidosis. These peptides tended to be distributed in
the myocytes predominantly on the endocardial side and near
amyloid deposits. 2) The ANP and BNP immunogenicities
were confined to specific granules of ventricular myocytes but
were not noted in the amyloid fibrils of the cardiac amyloidosis
specimens, unlike those of isolated atrial amyloidosis, where
their antigenicities were confirmed. 3) The plasma concentra-
tions of both ANP and BNP were elevated in the patients with
cardiac amyloidosis, and the elevation of BNP was more
extreme.
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